secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-05-21T23:59:59+00:00
Accession:  0001628280-24-024530
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine adopts Second Amended and Restated Bylaws with updated stockholder proposal procedures
--------------------------------------------------------------------------------

- Board adopted Second A&R Bylaws effective May 17, 2024, superseding prior bylaws.
- Revises advance notice procedures for stockholder proposals and director nominations.
- Addresses universal proxy rules; requires compliance with Rule 14a-19 for non-Board nominees.
- Clarifies Board meeting procedures including postponing, rescheduling, canceling stockholder meetings.
- Updates routine, technical, and non-substantive provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024024530/0001628280-24-024530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024024530/prme-20240517.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-024530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer